And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. And our agenda is rather modest, despite the extended holiday weekend on this side of the pond. We plan to manicure the Pharmalot grounds, hang with our short person, promenade with the official mascots, and catch up on our reading. And what about you? This continues to be a lovely time to enjoy the great outdoors — there are beaches, lakes, and mountains to explore. You could make time for someone special or indulge in a few naps. Or prepare your bunker now that you-know-who called off peace talks. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you on Tuesday …

Most companies that pay six figures to the majority of their workers are not big banks or money managers, but biotech firms that rely on medical researchers, according to an analysis by The Wall Street Journal. Four companies in the S&P 500 paid workers in the middle of their payrolls more than $200,000, and three of them are drug makers. At Incyte (INCY), Celgene (CELG), and Vertex Pharmaceuticals (VRTX), the middle-earners last year made $253,000, $213,000 and $211,500, respectively.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy